Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
GILD Analyst Ratings
Strong Buy
15 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GILD Stock 12 Month Forecast
Average Price Target
$121.53
▲(5.90%Upside)
| Highest Price Target$140.00 | Average Price Target$121.53 | Lowest Price Target$96.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$119
Buy
3.69%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Morgan Stanley
$135
Buy
17.64%
Upside
Reiterated
07/29/25
BMO Capital
$120
Buy
4.57%
Upside
Reiterated
07/28/25
Needham
$133
Buy
15.89%
Upside
Upgraded
07/25/25
Gilead Sciences' Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued PotentialWe are upgrading GILD to $133 PT following a positive physician survey for Yeztugo in HIV pre-exposure prophylaxis (PrEP), which gained US approval on 6/18/25. The survey suggests physicians see a ~49% increase from the current PrEP market by 2030 and Yeztugo capturing ~38% market share, which we believe is not adequately captured in current consensus models. Physicians have a favorable view of Yeztugo, citing dosing convenience as a key differentiator. ~70% of GILD's revenue comes from the HIV franchise, and we view Yeztugo as a key driver for the stock. The survey results increase our confidence that the drug could be a multi-billion-dollar contributor to topline growth over the next several years. We model Yeztugo revenue of $4.1B in 2030 (+10% above consensus) and $6.4B by 2035 (+20% above consensus).
Leerink Partners
$114
Buy
-0.66%
Downside
Reiterated
07/25/25
We expect discussion of USPSTF and implications for PrEP on Gilead's and Merck's 2Q25 earnings calls on Thursday, August 7th (GILD webcast) and Tuesday, July 29th (MRK webcast), respectively.
Bank of America Securities
$126
Buy
9.79%
Upside
Reiterated
07/24/25
TD Cowen
$110
Buy
-4.15%
Downside
Reiterated
07/23/25
Citi
$125
Buy
8.92%
Upside
Reiterated
07/21/25
J.P. Morgan
$109.27→$130
Buy
13.28%
Upside
Reiterated
07/11/25
Wells Fargo
$140
Buy
21.99%
Upside
Assigned
07/08/25
Bernstein
$120
Buy
4.57%
Upside
Assigned
07/08/25
RBC Capital
$95→$96
Hold
-16.35%
Downside
Reiterated
07/07/25
Jefferies
$130
Buy
13.28%
Upside
Reiterated
06/27/25
Oppenheimer
$125
Buy
8.92%
Upside
Reiterated
06/20/25
Mizuho Securities
$108→$117
Buy
1.95%
Upside
Reiterated
06/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$119
Buy
3.69%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Morgan Stanley
$135
Buy
17.64%
Upside
Reiterated
07/29/25
BMO Capital
$120
Buy
4.57%
Upside
Reiterated
07/28/25
Needham
$133
Buy
15.89%
Upside
Upgraded
07/25/25
Gilead Sciences' Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued PotentialWe are upgrading GILD to $133 PT following a positive physician survey for Yeztugo in HIV pre-exposure prophylaxis (PrEP), which gained US approval on 6/18/25. The survey suggests physicians see a ~49% increase from the current PrEP market by 2030 and Yeztugo capturing ~38% market share, which we believe is not adequately captured in current consensus models. Physicians have a favorable view of Yeztugo, citing dosing convenience as a key differentiator. ~70% of GILD's revenue comes from the HIV franchise, and we view Yeztugo as a key driver for the stock. The survey results increase our confidence that the drug could be a multi-billion-dollar contributor to topline growth over the next several years. We model Yeztugo revenue of $4.1B in 2030 (+10% above consensus) and $6.4B by 2035 (+20% above consensus).
Leerink Partners
$114
Buy
-0.66%
Downside
Reiterated
07/25/25
We expect discussion of USPSTF and implications for PrEP on Gilead's and Merck's 2Q25 earnings calls on Thursday, August 7th (GILD webcast) and Tuesday, July 29th (MRK webcast), respectively.
Bank of America Securities
$126
Buy
9.79%
Upside
Reiterated
07/24/25
TD Cowen
$110
Buy
-4.15%
Downside
Reiterated
07/23/25
Citi
$125
Buy
8.92%
Upside
Reiterated
07/21/25
J.P. Morgan
$109.27→$130
Buy
13.28%
Upside
Reiterated
07/11/25
Wells Fargo
$140
Buy
21.99%
Upside
Assigned
07/08/25
Bernstein
$120
Buy
4.57%
Upside
Assigned
07/08/25
RBC Capital
$95→$96
Hold
-16.35%
Downside
Reiterated
07/07/25
Jefferies
$130
Buy
13.28%
Upside
Reiterated
06/27/25
Oppenheimer
$125
Buy
8.92%
Upside
Reiterated
06/20/25
Mizuho Securities
$108→$117
Buy
1.95%
Upside
Reiterated
06/18/25
Best Analysts Covering Gilead Sciences
1 Month
xxx
Success Rate
21/31 ratings generated profit
Average Return
+2.93%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 67.74% of your transactions generating a profit, with an average return of +2.93% per trade.
3 Months
xxx
Success Rate
22/31 ratings generated profit
Average Return
+3.88%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +3.88% per trade.
1 Year
Success Rate
15/17 ratings generated profit
Average Return
+23.29%
reiterated a buy rating 21 days ago
Copying Chris Schott's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +23.29% per trade.
2 Years
xxx
Success Rate
17/17 ratings generated profit
Average Return
+34.01%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GILD Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
43
56
53
69
58
Hold
10
15
10
12
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
53
71
63
81
64
Each month's total comprises the sum of three months' worth of ratings.
GILD Financial Forecast
GILD Stock Forecast FAQ
What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 121.53.
What is GILD’s upside potential, based on the analysts’ average price target?
Gilead Sciences has 5.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GILD a Buy, Sell or Hold?
Gilead Sciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.
What is Gilead Sciences’s price target?
The average price target for Gilead Sciences is 121.53. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $96.00. The average price target represents 5.90% Increase from the current price of $114.76.
The highest analyst price target is $140.00 ,the lowest forecast is $96.00. The average price target represents 5.90% Increase from the current price of $114.76.
What do analysts say about Gilead Sciences?
Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of GILD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.